HOW IZERVAY WORKS
CLINICAL Study results
IZERVAY slowed GA progression in just one year
Slowing GA progression may help to preserve vision longer.
IZERVAY was evaluated in 2 clinical trials of over 700 people with GA. In both trials, GA progression was slower for people receiving IZERVAY compared to those that were not treated.
In just one year, compared to those that did not receive treatment,
IZERVAY slowed GA progression by:
IZERVAY slowed GA progression by:
Trial 1
(N=177)
35%
Slower Progression
in just one year of treatment
Trial 2
(N=447)
18%
Slower Progression
in just one year of treatment
How IZERVAY works
Only IZERVAY directly targets C5, a key source of retinal cell death and loss of photoreceptors
GA is related to immune system overactivity
In people with GA, a part of the immune system becomes overactive.
C5 signals an attack response
A protein called C5 signals other proteins to start attacking retinal cells.
IZERVAY
blocks C5
blocks C5
IZERVAY blocks the C5 protein to help protect healthy retinal cells and photoreceptors.
Side effects
IZERVAY was studied in 2 clinical trials
Less than 2% of people stopped treatment due to side effects.
The most common side effects experienced at 12 months were:
Treated with
IZERVAY (n=292) |
Not treated with
IZERVAY (n=332) |
|
---|---|---|
Blood in the white of the eye | 13% | 9% |
Increased eye pressure | 9% | 1% |
Blurred vision* | 8% | 5% |
Wet AMD | 7% | 4% |
Eye pain | 4% | 3% |
Spots in vision | 2% | <1% |
Eyelid inflammation | 2% | <1% |
*Blurred vision includes visual impairment and/or loss of sharpness or detail
in vision at a distance.
These are not all the possible side effects of IZERVAY. Talk to your doctor if you think you might be
experiencing side effects.
Ready to explore treatment?
See what to expect from your treatment with IZERVAY.